Related Experiment Videos
Converting enzyme inhibition and progressive glomerulosclerosis in the rat
J J Beukers1, A van der Wal, P J Hoedemaeker
1Department of Pathology, State University of Leiden, The Netherlands.
Kidney International
|December 1, 1987
Summary
Early angiotensin-converting enzyme inhibition with captopril prevents glomerulosclerosis and proteinuria in rats after uninephrectomy. However, it does not reverse established disease.
Area of Science:
- Nephrology
- Pharmacology
- Experimental Medicine
Background:
- Uninephrectomy (UN) in rats leads to glomerulosclerosis (GS) and proteinuria.
- Angiotensin-converting enzyme inhibition (CEI) is a therapeutic strategy for kidney disease.
Purpose of the Study:
- To investigate the effect of captopril (CAP) on the development and progression of glomerulosclerosis (GS) in uninephrectomized (UN) rats.
- To determine if early versus late CEI influences outcomes.
Main Methods:
- Six groups of male Wistar rats underwent uninephrectomy (UN).
- Groups received varying durations of captopril (CAP) treatment (500 mg/liter drinking water) or served as controls.
- Systolic blood pressure (SBP), proteinuria, and glomerular sclerosis (GS) incidence were assessed.
Main Results:
- Early CAP treatment (4-5 weeks post-UN) reduced SBP, filtration fraction, and glomerular volumes.
- Long-term CAP (8 months post-UN) significantly lowered SBP, reduced proteinuria, and decreased GS incidence (0-1.5%) compared to controls (9.1-29.7%).
- Late CAP treatment initiated after proteinuria and GS developed showed no effect on SBP, proteinuria, or GS progression.
Conclusions:
- Early CEI with captopril effectively prevents progressive proteinuria and glomerulosclerosis in rats following uninephrectomy.
- CEI initiated after significant proteinuria and GS has developed does not impact disease progression or blood pressure.